TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Schedule of Income Tax (Benefit)/Provision (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Current
Deferred	(5,914,000)	(6,219,000)
Change in Valuation Allowance	5,914,000	6,219,000
Income Tax Benefit

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.